Janssen Search
Search results
Johnson & Johnson Pharmaceutical Business Review
Johnson & Johnson will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday, May 15, 2019, at the Hyatt Regency Hotel in New Brunswick, New Jersey, and ending at approximately 2 ...
William (Bill) J. Martin, Ph.D.
WILLIAM (BILL) J. MARTIN, PH.D. GLOBAL NEUROSCIENCE THERAPEUTIC AREA HEAD Bill Martin is the Global Neuroscience Therapeutic Area Head at Johnson & Johnson Innovative Medicine and a member of the company’s Group Operating Committee. He leads a ...
About DIA
The Disease Interception Accelerator The Disease Interception Accelerator (DIA), part of Janssen Research & Development, LLC, is working to harness cutting-edge science to seek the most tractable interception opportunities to identify and address the ...
Janssen Recognizes World Psoriasis Day
Janssen Recognizes World Psoriasis Day The Janssen Pharmaceutical Companies of Johnson & Johnson join the International Federation of Psoriasis Associations in support of World Psoriasis Day on October 29, an annual event dedicated to raising ...
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Nov 20, 2018 At a small company in Rockville, Maryland, a handful of researchers are working on viruses that can be tailored to avoid ...
Accelerating Hope for Children
Accelerating Hope for Children For nearly 20 years, Janssen, the pharmaceutical companies of Johnson & Johnson (J&J), have been working to bring hope to the millions of children with serious diseases worldwide. With a science- and evidence-based ...
Human Microbiome Institute
Human Microbiome Institute Human Microbiome Institute Microbial artwork credit: Mehmet Berkmen, Ph.D. and Maria Peñil Human Microbiome Institute Header Our Vision Article Our Approach Article Our Work Resources Title Join Our Team We are seeking ...
Bert Hartog, Ph.D.
Bert Hartog, Ph.D. SENIOR DIRECTOR, JCI Bert is the Senior Director and Innovation Leader for Janssen Clinical Innovation based in Belgium. As an industry expert in global clinical operations and digital health, he leads transformational innovation ...
Gastroenterology – Exploring IBD, Crohn’s and UC
Gastroenterology: Leading the Way to a Cure by Redefining the Treatment Paradigm Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis (UC), is a key area of focus for Janssen. Since introducing the first tumor necrosis ...
Janssen Announces Update to Phase 3 MACiTEPH Study Evaluating Macitentan 75mg in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Sep 06, 2023 United States RARITAN, NJ, September 6, 2023- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its decision to stop the Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with Chronic Thromboembolic ...